Anne Schoenmakers

Dr. Anne Schoenmakers

NLR International Office, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KUKedir Urgesa
Kedir Urgesa
NBNaomi D. de Bruijne
Naomi D. de Bruijne
KBKidist Bobosha
Kidist Bobosha
BSBerhanu Seyoum
Berhanu Seyoum
AMAdane Mihret
Adane Mihret
AAAbraham Aseffa
Abraham Aseffa
Background: Leprosy or Hansen’s disease is known to cause disability and disfigurement. A delay in case detection of leprosy patients can lead to severe outcomes. In Ethiopia, the disability rates caused by leprosy among new cases are relatively high compared to other endemic countries. This suggests the existence of hidden leprosy cases in the community and a delay in timely detection. To reduce disability rates, it is crucial to identify the factors associated with this delay. This study aimed to determine the extent of delay in case detection among leprosy cases in Eastern Ethiopia. Methods: This cross-sectional explorative study was conducted in January and February 2019 among 100 leprosy patients diagnosed ≤6 months prior to inclusion. A structured questionnaire was used to collect data, including the initial onset of symptoms, and the reasons for delayed diagnosis. Descriptive statistics, including percentages and medians, were used to describe the case detection delay. Logistic regression analysis was carried out to evaluate the predictors of delay in case detection of >12 months. Findings: The median age of patients was 35 years, with a range of 7 to 72 years. The majority were male (80%) and rural residents (90%). The median delay in case detection was 12 months (interquartile range 10–36 months) among the included patients. The mean delay in case detection was 22 months, with a maximum delay of 96 months. The overall prevalence of disability among the study population was 42% (12% grade I and 30% grade II). Fear of stigma (p = 0.018) and experiencing painless symptoms (p = 0.018) were highly associated with a delay in case detection of >12 months. Conclusions: Being afraid of stigma and having painless symptoms, which are often misinterpreted as non-alarming at the onset of the disease, were associated with a delay in case detection. This study showed the need to increase knowledge on early symptoms of leprosy among affected communities. Furthermore, it is important to support initiatives that reduce leprosy related stigma and promote health worker training in leprosy control activities.

26 August 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
ASAnne Schoenmakers
Anne Schoenmakers
THThomas Hambridge
Thomas Hambridge
RWRobin van Wijk
Robin van Wijk
Christa KasangChrista Kasang
Christa Kasang
JRJan Hendrik Richardus
Jan Hendrik Richardus
LMLiesbeth Mieras
Liesbeth Mieras
Introduction Leprosy, or Hansen’s disease, remains a cause of preventable disability. Early detection, treatment and prevention are key to reducing transmission. Post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) reduces the risk of developing leprosy when administered to screened contacts of patients. This has been adopted in the WHO leprosy guidelines. The PEP4LEP study aims to determine the most effective and feasible method of screening people at risk of developing leprosy and administering chemoprophylaxis to contribute to interrupting transmission. Methods and analysis PEP4LEP is a cluster-randomised implementation trial comparing two interventions of integrated skin screening combined with SDR-PEP distribution to contacts of patients with leprosy in Ethiopia, Mozambique and Tanzania. One intervention is community-based, using skin camps to screen approximately 100 community contacts per leprosy patient, and to administer SDR-PEP when eligible. The other intervention is health centre-based, inviting household contacts of leprosy patients to be screened in a local health centre and subsequently receive SDR-PEP when eligible. The mobile health (mHealth) tool SkinApp will support health workers’ capacity in integrated skin screening. The effectiveness of both interventions will be compared by assessing the rate of patients with leprosy detected and case detection delay in months, as well as feasibility in terms of cost-effectiveness and acceptability. Ethics and dissemination Ethical approval was obtained from the national ethical committees of Ethiopia (MoSHE), Mozambique (CNBS) and Tanzania (NIMR/MoHCDEC). Study results will be published open access in peer-reviewed journals, providing evidence for the implementation of innovative leprosy screening methods and chemoprophylaxis to policymakers. Trial registration number NL7294 (NTR7503).

1 January 2020 in Research and Reports in Tropical Medicine
Verified
Journal Article
Open access
PDF file
ASAnne Schoenmakers
Anne Schoenmakers
LMLiesbeth Mieras
Liesbeth Mieras
TBTeky Budiawan
Teky Budiawan
WBWim H van Brakel
Wim H van Brakel
Objective: Annually, over 200,000 people are diagnosed with leprosy, also called Hansen's disease. This number has been relatively stable over the past years. Progress has been made in the fields of chemoprophylaxis and immunoprophylaxis to prevent leprosy, with a primary focus on close contacts of patients. In this descriptive meta-analysis, we summarize the evidence and identify knowledge gaps regarding post-exposure prophylaxis against leprosy. Methods: A systematic literature search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology was conducted by searching the medical scientific databases Cochrane, Embase, Pubmed/MEDLINE, Research Gate, Scopus and Web of Science on Jan. 22, 2020, using a combination of synonyms for index terms in four languages: "leprosy" and "population" or "contacts" and "prevention" or "prophylaxis." Subsequently, Infolep.org and Google Scholar were searched and the "snowball method" was used to retrieve other potentially relevant literature. The found articles were screened for eligibility using predetermined inclusion and exclusion criteria. Results: After deduplication, 1,515 articles were screened, and 125 articles were included in this descriptive meta-analysis. Immunoprophylaxis by bacillus Calmette-Guerin (BCG) vaccination is known to provide protection against leprosy. The protection it offers is higher in household contacts of leprosy patients compared with the general population and is seen to decline over time. Contact follow-up screening is important in the first period after BCG administration, as a substantial number of new leprosy patients presents three months postvaccination. Evidence for the benefit of re-vaccination is conflicting. The World Health Organization (WHO) included BCG in its Guidelines for the Diagnosis, Treatment and Prevention of Leprosy by stating that BCG at birth should be maintained in at least all leprosy high-burden regions. Literature shows that several vaccination interventions with other immunoprophylactic agents demonstrate similar or slightly less efficacy in leprosy risk reduction compared with BCG. However, most of these studies do not exclusively focus on post-exposure prophylaxis. Two vaccines are considered future candidates for leprosy prophylaxis: Mycobacterium indicus pranii (MiP) and LepVax. For chemoprophylaxis, trials were performed with dapsone/acedapsone, rifampicin, and ROM, a combination of rifampicin, ofloxacin, and minocycline. Single-dose rifampicin is favored as post-exposure prophylaxis, abbreviated as SDR-PEP. It demonstrated a protective effect of 57% in the first two years after administration to contacts of leprosy patients. It is inexpensive, and adverse events are rare. The risk of SDR-PEP inducing rifampicin resistance is considered negligible, but continuous monitoring in accordance with WHO policies should be encouraged. The integration of contact screening and SDR-PEP administration into different leprosy control programs was found to be feasible and well accepted. Since 2018, SDR-PEP is included in the WHO Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. Conclusion: Progress has been made in the areas of chemoprophylaxis and immunoprophylaxis to prevent leprosy in contacts of patients. Investing in vaccine studies, like LepVax and MiP, and increasing harmonization between tuberculosis (TB) and leprosy research groups is important. SDR-PEP is promising as a chemoprophylactic agent, and further implementation should be promoted. More chemoprophylaxis research is needed on: enhanced medication regimens; interventions in varying (epidemiological) settings, including focal mass drug administration (fMDA); specific approaches per contact type; combinations with screening variations and field-friendly rapid tests, if available in the future; community and health staff education; ongoing antibiotic resistance surveillance; and administering chemoprophylaxis with SDR-PEP prior to BCG administration. Additionally, both leprosy prophylactic drug registration nationally and prophylactic drug availability globally at low or no cost are important for the implementation and further upscaling of preventive measures against leprosy, such as SDR-PEP and new vaccines.

13 January 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
NBNaomi D. de Bruijne
Naomi D. de Bruijne
KUKedir Urgesa
Kedir Urgesa
AAAbraham Aseffa
Abraham Aseffa
KBKidist Bobosha
Kidist Bobosha
ASAnne Schoenmakers
Anne Schoenmakers
LMLiesbeth Mieras
Liesbeth Mieras
Background: Delay in case detection is a risk factor for developing leprosy-related impairments, leading to disability and stigma. The objective of this study was to develop a questionnaire to determine the leprosy case detection delay, defined as the period between the first signs of the disease and the moment of diagnosis, calculated in total number of months. The instrument was developed as part of the PEP4LEP project, a large-scale intervention study which determines the most effective way to implement integrated skin screening and leprosy post-exposure prophylaxis with a single-dose of rifampicin (SDR-PEP) administration in Ethiopia, Mozambique and Tanzania. Methodology/Principal findings: A literature review was conducted and leprosy experts were consulted. The first draft of the questionnaire was developed in Ethiopia by exploring conceptual understanding, item relevance and operational suitability. Then, the first draft of the tool was piloted in Ethiopia, Mozambique and Tanzania. The outcome is a questionnaire comprising nine questions to determine the case detection delay and two annexes for ease of administration: a local calendar to translate the patient’s indication of time to number of months and a set of pictures of the signs of leprosy. In addition, a body map was included to locate the signs. A ‘Question-by-Question Guide’ was added to the package, to provide support in the administration of the questionnaire. The materials will be made available in English, Oromiffa (Afaan Oromo), Portuguese and Swahili via https://www.infolep.org. Conclusions/Significance: It was concluded that the developed case detection delay questionnaire can be administered quickly and easily by health workers, while not inconveniencing the patient. The instrument has promising potential for use in future leprosy research. It is recommended that the tool is further validated, also in other regions or countries, to ensure cultural validity and to examine psychometric properties like test-retest reliability and interrater reliability.

Verified
Journal Article
Open access
PDF file
NMNelly Mwageni
Nelly Mwageni
RWRobin van Wijk
Robin van Wijk
FDFufa Daba
Fufa Daba
EGEphrem Mamo Gebrehiwot
Ephrem Mamo Gebrehiwot
KDKitesa Debelo
Kitesa Debelo
SMStephen Mshana
Stephen Mshana
Background: The prevalence of skin diseases such as leprosy, and limited dermatological knowledge among frontline health workers (FHWs) in rural areas of Sub-Saharan Africa, led to the development of the NLR SkinApp: a mobile application (app) that supports FHWs to promptly diagnose and treat, or suspect and refer patients with skin diseases. The app includes common skin diseases, neglected tropical skin diseases (skin NTDs) such as leprosy, and HIV/AIDS-related skin conditions. This study aimed to test the supporting role of the NLR SkinApp by examining the diagnostic accuracy of its third edition. Methods: A cross-sectional study was conducted in East Hararghe, Ethiopia, as well as the Mwanza and Morogoro region, Tanzania, in 2018–2019. Diagnostic accuracy was measured against a diagnosis confirmed by two dermatologists/dermatological medical experts (reference standard) in terms of sensitivity, specificity, positive predictive value, and negative predictive value. The potential negative effect of an incorrect management recommendation was expressed on a scale of one to four. Results: A total of 443 patients with suspected skin conditions were included. The FHWs using the NLR SkinApp diagnosed 45% of the patients accurately. The values of the sensitivity of the FHWs using the NLR SkinApp in determining the correct diagnosis ranged from 23% for HIV/AIDS-related skin conditions to 76.9% for eczema, and the specificity from 69.6% for eczema to 99.3% for tinea capitis/corporis. The inter-rater reliability among the FHWs for the diagnoses made, expressed as the percent agreement, was 58% compared to 96% among the dermatologists. Of the management recommendations given on the basis of incorrect diagnoses, around one-third could have a potential negative effect. Conclusions: The results for diagnosing eczema are encouraging, demonstrating the potential contribution of the NLR SkinApp to dermatological and leprosy care by FHWs. Further studies with a bigger sample size and comparing FHWs with and without using the NLR SkinApp are needed to obtain a better understanding of the added value of the NLR SkinApp as a mobile health (mHealth) tool in supporting FHWs to diagnose and treat skin diseases.

1 March 2024 in Leprosy Review
Verified
Journal Article
Open access
PDF file
ARAYMEE MEDEIROS DA ROCHA
AYMEE MEDEIROS DA ROCHA
ESEliana Amorim de Souza
Eliana Amorim de Souza
AFAnderson Fuentes Ferreira
Anderson Fuentes Ferreira
NFNágila Nathaly Lima Ferreira
Nágila Nathaly Lima Ferreira
ARAdriana da Silva dos Reis
Adriana da Silva dos Reis
JSJosé Alexandre Menezes da Silva
José Alexandre Menezes da Silva
Introduction & Aim Brazil, ranking second globally in newly detected leprosy (Hansen's disease) patients, has encountered obstacles in advancing leprosy control amidst the Covid-19 pandemic, particularly in more vulnerable regions. This study aims to characterize the psychosocial as well as health status and needs of individuals affected by leprosy during the Covid-19 pandemic in the North and Northeast regions of Brazil. Methods This is a descriptive cross-sectional study examining the health status and needs of persons affected by leprosy during the Covid-19 pandemic throughout the years 2019 and 2020. Adults receiving multidrug therapy (MDT) who were registered in the National System of Notifiable Diseases during this period and lived in the North and Northeast regions of Brazil were included. After obtaining consent, data collection involved conducting telephone surveys. Referrals to additional care were provided to study participants in need. Data collected were entered into REDCap, with subsequent data extracted using TabWin® software from the Department of Informatics of the Brazilian Unified Health System. We conducted a descriptive analysis of sociodemographic, clinical-epidemiological, and psychosocial variables using STATA. Logistic regression analysis was used to estimate the odds ratio (OR) with 95% confidence intervals (95% CI). Results The study included 346 persons affected by leprosy who were receiving leprosy treatment. Interruption of MDT occurred in 31.8%, among these patients, 22.5% reported that the interruption had a relationship with the pandemic. Of the included participants, 35.3% reported that their household contacts were not screened for leprosy, although 14.2% recognized skin lesions with loss of sensitivity in their contacts. When assessing mental wellbeing, sadness was reported by 32.4%, fear by 35.3%, sleep deprivation by 34.7%, and depression by 9.8% of the participants. We observed an association between loss of income and sadness (OR 1.61; 95%CI 1.02–2.54; p-value 0.040) and reported depression (OR 2.35; 95%CI 1.11–4.98; p-value 0.026). Social distancing had an additional financial impact on 32.3% of persons affected by leprosy in this study. Discussion & Conclusion The pandemic had significant economic, social, and health impacts on the lives of persons affected by leprosy, further complicating leprosy control efforts. Medication availability, medical and psychological patient follow-up, as well as contact screening, were hindered during the pandemic, making the control of leprosy even more challenging. Recognizing the weaknesses of the leprosy control program is crucial for enhancing services both presently and in preparation for future crises like pandemics. Brazil could enhance leprosy control services by implementing novel disease control strategies, including additional prevention measures for contacts. In addition to the necessary improvements needed at the clinical health system level, addressing social vulnerability and enhancing individual mental wellbeing are urgent priorities. This could be achieved through initiatives such as offering counseling and establishing peer-support groups.